

**PERSONAL INFORMATION**

Giovanna Paolone

- 📍 Department of Diagnostic and Public Health, Pharmacology Section  
P.le Scuro 10, 37134 Verona (VR)
- ☎ +39 045 802 7224 (office)
- ✉ giovanna.paolone@univr.it

**POSITION** Assistant Professor

**WORK EXPERIENCE**

---

- December 2019 – to present** Assistant Professor (Senior)  
Department of Diagnostic and Public Health,  
University of Verona, Verona, Italy
- June 2018 – to November 2019** Assistant Professor (Junior)  
Department of Diagnostic and Public Health,  
University of Verona, Verona, Italy
- September 2017 – May 2018** Research Scientist (Dr. Mario Buffelli)  
Department of Neurosciences, Biomedicine and Movement Sciences,  
Section of Physiology and Psychology,  
University of Verona, Verona, Italy
- November 2015 – August 2017** Research scientist (Dr. Michele Simonato)  
Department of Medical Sciences, Section of Pharmacology  
University of Ferrara, Ferrara, Italy
- April – October 2015** Marie Curie Industry-Academia Partnerships and Pathways (FP7 MC-IAPP)  
NsGene, Providence, RI, USA
- October 2013 – March 2015** Research scientist (Dr. Michele Morari)  
Department of Medical Sciences, Section of Pharmacology  
University of Ferrara, Ferrara, Italy
- May – September 2013** Researcher  
Institute of Genetics and Biophysics "A. Buzzati Traverso" National Research Council, Naples (Italy)
- December 2010 – April 2013** Assistant Research Scientist (Dr. Martin Sarter)  
University of Michigan, Ann Arbor, United States.
- May 2008 – November 2010** Post Doctoral Fellow (Dr. Martin Sarter and Dr. Theresa Lee)  
University of Michigan, Ann Arbor (United States)

January 2006 –  
April 2008

Post Doctoral Fellow (Dr. Jane Stewart)

Center for Studies in Behavioral Neurobiology, Concordia University, Montreal  
(Canada)

February 2003 –  
May 2003

Research Associated (Dr. Jane Stewart)

Center for Studies in Behavioral Neurobiology, Concordia University, Montreal  
(Canada)

## EDUCATION AND TRAINING

---

November 2001 –  
December 2005

PhD in Pharmacology

Sapienza, University of Rome, Rome (Italy)

October 1997 – July 2001

Honors in Laurea (a 5-years university degree) Experimental Psychology

Sapienza, University of Rome, Rome (Italy)

## PERSONAL SKILLS

---

EDITORIAL  
BOARD(Journal)

Brain Sciences

AD HOC EDITORIAL  
CONSULTING (Journal)

Molecular Neurobiology  
Neurobiology of Disease  
Psychopharmacology  
Cytotherapy  
Experimental Neurology  
Journal of Pineal Research

## REVIEWER FOR GRANT AGENCIES

The EU Framework for Research and Innovation  
Synergy Program – European Research Council

## QUALIFICATION

National scientific qualification to serve as an associate professor of Pharmacology in the Italian universities (*Abilitazione Scientifica Nazionale*, 2021, settore **concorsuale 05/G1; SSD: Bio14; seconda fascia**)  
<https://asn18.cineca.it/pubblico/miur/esito/05%252FG1/2/6>

National scientific qualification to serve as an associate professor in the Italian universities in the area of Biopsychology, Psychometrics and General

Psychology (*Abilitazione Scientifica Nazionale*, 2012, settore **concorsuale 11/E1; SSD: M-PSI 01, 02, 03; seconda fascia**)  
<http://abilitazione.miur.it/public/pubblicarisultati.php>

Marie Skłodowska Curie Ambassador

**RESEARCH SUPPORT**

2022

Co-Responsabile Scientifico (Co-PI), **The Michael J. Fox Foundation for Parkinson's Research** - Accelerating Early Proof-of-Concept Testing of Promising PD Therapies  
*Title:* PDRepair, a novel combined neurorestorative and precision therapy for GBA Parkinson's disease

2020

Principal Investigator, **Bando di Ateneo per la Ricerca di Base**;  
*Title:* From the gut to the brain and back: novel therapeutic approaches for the treatment of Parkinson disease as network dysfunction.

2020

Principal Investigator, **Sinfonia Biotherapeutics, AB**, Huddinge, Sweden;  
*Title:* neuroprotective effects of progranulin, prosaposin, GDNF and combinations thereof in a rat 6-OHDA model of Parkinson's disease.

2019

Principal Investigator, **Sinfonia Biotherapeutics, AB**, Huddinge, Sweden;  
*Title:* Long-term progranulin secretion from devices implanted into rat Striatum.

2019

Principal Investigator, University of Verona, **FURDIPSP\_ASS\_FARMA**;  
*Title:* Effetti della terapia basata su cellule umane incapsulate e ingegnerizzate per il rilascio di GDNF su modelli animali di malattia di Parkinson.

2019

Principal Investigator, Progetto finanziato da **Brain Research Foundation Verona**;  
*Title:* Trattamento della malattia di Parkinson in un modello di ratto che esprime  $\alpha$ -sinucleina umana con cellule umane incapsulate e ingegnerizzate per il rilascio di GDNF.

2019

Co- Principal Investigator, **Zardi-Gori Foundation**;  
*Titolo:* A novel therapeutic approach for dopamine agonists medication-induced Impulse Control Disorders.

**AWARDS**

- Citizen of Excellence of the city of Verona for scientific achievements conferred by the Mayor - Verona, Italy, January 9th, 2020
- Brain Research Foundation Verona – Post-Doctoral Fellowship 2019
- International Association of Advanced Material Scientist Medal for outstanding research in the field of New Age

- Technology and Innovations. Stockholm, October 10<sup>th</sup>, 2018
- Pharmacology Society Meeting (Barcelona, Spain, 2005; Tübingen, Germany, 2007)
- Travel Bursary to attend the Biennial European Behavioral
- Italian Society of Pharmacology (SIF): Fellowship to support foreign research activity (2006 and 2003)
- Paid part-time positions based on excellence at “Sapienza” University of Rome (Teaching and Library assistant 2001; 2000)

#### TEACHING EXPERIENCE

- Pharmacology and cardiology applied to physical activity – Sport and Exercise Science – University of Verona (coordinator, 96 hrs).
- Sports and drugs – Master’s degree in preventive and adapted exercise science – University of Verona; (coordinator, 24 hrs).
- Pharmacological Sciences – Biomedical Laboratory Techniques – University of Verona; (20 hrs).

#### AFFILIATION SCIENTIFIC SOCIETIES

Society for Neuroscience  
 Società Italiana di Farmacologia  
 Società Italiana di Neuroscienze  
 European Behavioral Pharmacology Society  
 FIE - Federazione Italiana Epilessia  
 The International College of Neuropsychopharmacology

#### MAIN NATIONAL AND INTERNATIONAL SCIENTIFIC COLLABORATION

*Gloriana Therapeutics, Inc.*, Warren, RI, USA – Brain Repair Device –  
*Sinfonia Biotherapeutics, Inc.*, Huddinge, Sweden - Precision therapies for genetically-defined dementia & related neurodegenerative diseases  
 Department of Pharmacology, *University of Ferrara*, FE, Italy  
 Department of Neurosciences, Biomedicine and Movement Sciences  
*University of Verona*, VR, Italy

#### BOOK CHAPTER

1- Falcicchia C, **Paolone G**, Simonato M  
 Cell Therapy for Epilepsy in *Cell Therapy: Current Status and Future Directions* (DF Emerich., & G. Orive Eds.), Springer International Publishing, New York, NY, USA 2017.  
 ISSN 2197-7852

#### 2 - **Paolone G**

From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson’s Disease  
 in *Prime Archives in Neuroscience* (J F Maya-Vetencourt), Vide Leaf, Hyderabad, India 2021  
 ISBN: 978-93-90014-30-9

ARTICLES IN REFEREED JOURNALS

1. Paolone G, Burdino R, Badiani A. (2003) Dissociation in the modulatory effects of environmental novelty on the locomotor, analgesic, and eating response to acute and repeated morphine in the rat. *Psychopharmacology* 166:146-155.
2. Antonilli L, Suriano C, Paolone G, Badiani A, Nencini P. (2003) Repeated exposures to heroin and/or cadmium alter the rate of formation of morphine glucuronides in the rat. *J Pharmacol Exp Ther* 307: 651-660.
3. Paolone G, Paolopoli M, Marrone MC, Nencini P, Badiani A. (2004) Environmental modulation of the interoceptive effects of amphetamine in the rat. *Behav Brain Res* 152:149-155.
4. Scaccianoce S, Del Bianco P, Paolone G, Caprioli D, Modafferi AM, Nencini P, Badiani A. (2006) Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone. *Behav Brain Res* 168:323-5.
5. Botreau F, Paolone G, Stewart J. (2006) d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. *Behav Brain Res* 172:173-8.
6. Caprioli D, Paolone G, Celentano M, Testa A, Nencini P, Badiani A. (2007) Environmental modulation of cocaine self-administration in the rat. *Psychopharmacology* 192:397-406.
7. Paolone G, Conversi D, Caprioli D, Del Bianco PD, Nencini P, Cabib S, Badiani A. (2007) Modulatory effect of environmental context and drug history on heroin-induced psychomotor activity and fos protein expression in the rat brain. *Neuropsychopharmacology* 32:2611-23.
8. Caprioli D, Celentano M, Paolone G, Badiani A. (2007) Modeling the role of environment in addiction. *Prog Neuropsychopharmacol Biol Psychiatry* 31:1639-53.
9. Caprioli D, Celentano M, Paolone G, Lucantonio F, Bari A, Nencini P, Badiani A. (2008) Opposite environmental regulation of heroin and amphetamine self-administration in the rat. *Psychopharmacology* 198:395-404.
10. Paolone G, Botreau F, Stewart J. (2009) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. *Psychopharmacology* 202:403-409.
11. Sarter M & Paolone G. (2011) Deficits in attentional control:

cholinergic mechanisms and circuits-based treatment approaches. *Behavioral Neurosci.* Dec; 125(6):825-35.

12. Paolone G, Lee TM, Sarter M. (2012) Time to pay attention: attentional performance time-stamped prefrontal cholinergic activation, diurnality and performance. *J. Neurosci.* Aug 2012, 32(35): 12115-12128.
13. Paolone G, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. *J. Neurosci.* May 2013, 33(19): 8321-8335.
14. Paolone G\*, Mallory C, Koshy Cherian A, Sarter M. Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits. *Neuropharmacology*, Aug 2013, 16; 75C:274-285.
15. Kucinski A, Paolone G, Bradshaw M, Albin RL, Sarter M. Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. *J. Neurosci.* October 2013, 33(42): 16522-39.
16. Grupe M, Paolone G, Jensen AA, Sandager-Nielsen K, Sarter M, Grunnet M. Selective potentiation of  $(\alpha 4)_3(\beta 2)_2$  nicotinic acetylcholine receptors augments amplitudes of prefrontal nicotine-evoked glutamatergic transients in rats. *Biochem Pharmacol* 2013 Nov; 86(10): 1487-96.
17. Cristino L\*, Luongo L\*, Squillace M\*, Paolone G, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, Nisticò R®, Usiello A®. d-Aspartate oxidase, influences glutamatergic system homeostasis in mammalian brain. *Neurobiol Aging* 2015 Feb; (15): 1-13.
18. Paolone G, Brugnoli A, Arcuri A, Mercatelli D and Morari M. Eltoprazine prevents ledodopa-induced dyskinésias by reducing striatal glutamate and direct pathway activity. *Mov Disord.* Nov 2015, 30 (13): 1728-38.
19. Sacchi S\*, De Novellis V\*, Paolone G\*, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassineti M, Bertolino A, Pollegioni L, Morari M, Maione A, Errico F, Usiello A. Olanzapine but not clozapine increases glutamate release in the pre-frontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. *Scientific Report*; Apr 2017 10;7:46288.
20. Paolone G, Falcicchia C, Verlengia G, Barbieri M, Binaschi A,

Paliotto F, Paradiso B, Soukupova M, Zucchini S, Simonato M. A refined technique for microinjections in the rodent brain. *J Vis Exp.* Jan 2018 24;131.

**21.** Falcicchia C, Paolone G, Emerich DF, Lovisari F, Bell W, Fradet T, Wahlberg LU, Simonato M. Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy. *Mol Ther Methods Clin Dev.* 2018 Mar 9;9:211-224.

**22.** Paolone G, Falcicchia C, Lovisari F, Kokaia M, Bell W, Fradet T, Wahlberg LU, Emerich DF, Simonato M. Long-term, targeted delivery of GDNF from encapsulated cells is neuroprotective and reduces seizures in the pilocarpine model of epilepsy. *J. Neurosci.* 2019 39(11):2144-2156.

**23.** Emerich DF, Kordower JH, Chu Y, Thanos C, Bintz B, Paolone G, and Wahlberg LU. Widespread striatal delivery of gdnf from encapsulated cells prevents the anatomical and functional consequences of excitotoxicity. *Neural Plast.* 11;2019:6286197.

**24.** Piva A, Gerace E, Di Chio M, Padovani L, Paolone G, Pellegrini-Giampietro DE, Chiamulera C. Reconsolidation of sucrose instrumental memory in rats: the role of retrieval context. *Brain Res.* 1714:193-201.

**25.** Pedrazzoli M, Losurdo M, Paolone G, Avesani A, Coco S, Buffelli M (2018). Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's Disease. *Neurobiology of Disease.* Aug 5;132:104568.

**26.** Orive G, Echave MC, Dolatshahi-Pirouz A, **Paolone G**, Emerich DF. (2019) Advances in Cell-laden Hydrogels for Delivering Therapeutics. *Expert Opin Biol Ther.* Aug 26:1-4.

**27.** Piva A, Caffino L, Padovani L, Pintori N, Mottarlini F, Sferrazza G, **Paolone G**, Fumagalli F, Chiamulera C. (2020) The metaplastic effects of ketamine on renewal and reconsolidation of sucrose contextual memory in rats. *Behav Brain Res* 2020 Feb 379:112347.

**28.** **Paolone G**, Wahlberg LU, Policastro G, and Emerich DF. (2020) Encapsulated cell therapy for the treatment of epilepsy. *Current Neurobiology.* 11(1):04-07.

**29.** Wahlberg LU, Emerich DF, Kordower JH, Bell W, Fradet T, **Paolone G.** (2020) Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig

brain.

Current Research in Pharmacology and Drug Discovery. 1:19-29.

30. Izeia L, Eufrasio-da-Silva T, Dolatshahi-Pirouz A, Ostrovidov S, **Paolone G**, Peppas N, De Vos P, Emerich DF, Orive G. (2020) Cell-laden alginate hydrogels: the progress of living medicines for drug delivery  
Expert Opinion in Drug Del. Aug 17(8):1113-1118.
31. **Paolone G.** (2020) From the gut to the brain and back: novel therapeutic approaches for the treatment of Parkinson Disease as network dysfunction.  
Front Neurol. Oct 7;11:557928
32. Lovisari F,\* Roncon P,\* Soukoupova M, **Paolone G**, Labasque M, Inguscio S, Falcicchia C, Johnson M, Rossetti T, Petretto E, Leclercq K, Kaminski RM, Moyon B, Webster Z, Michele Simonato M\*\* and Zucchini S\*\*. (2020) Implication of Sestrin3 in epilepsy and its comorbidities.  
Brain Communications. Oct 9; 3(1):fcaa130
33. Policastro G, Brunelli M, Tinazzi M, Chiamulera C, Emerich DF, and **Paolone G.** (2020) Cytokines-, neurotrophins- and motor rehabilitation-induced plasticity in Parkinson's disease.  
Neural Plast. 2020 Nov 26;2020:8814028.
34. Amalric M, Patti T, Sotiropoulos I, Silva JM, Sousa N, Ztaou S, Chiamulera C, Wahlberg LU, Emerich DF and **Paolone G.** (2021) Where dopaminergic and cholinergic systems interact: a gateway for tuning neurological and psychiatric disorders.  
Frontiers in Behavioral Neuroscience. Jul 22; 15:661973
35. Chiamulera C, Benvegnù G, Piva A, **Paolone G.** Ecocebo: How the interaction between environment and drug effects may improve pharmacotherapy outcomes.  
Neurosci Biobehav Rev. 2024 Jun;161:105648. doi: 10.1016/j.neubiorev.2024.105648.
36. Lunghi C, Valetto MR, Caracciolo AB, Bramke I, Caroli S, Bottoni P, Castiglioni S, Crisafulli S, Cuzzolin L, Deambrosis P, Giunchi V, Grisotto J, Marcomini A, Moretti U, Murgia V, Pandit J, Polesello S, Poluzzi E, Romizi R, Scarpa N, Scroccaro G, Sorrentino R, Sundström A, Wilkinson J, **Paolone G.** Call to action: Pharmaceutical residues in the environment: threats to ecosystems and human health.  
Drug Saf. 2024 Dec 10. doi: 10.1007/s40264-024-01497-3.  
Salzano S, Bertasini C, Lundkvist J, Wahlberg LU, Chiamulera C, Vattemi G, Gardoni F, **Paolone G.** Frontotemporal dementia as a consequence of *GRN* mutations (Review – under review)

Bertasini C\*, Rossini M\*, Grisotto J, Wahlberg LU, Lundkvist J, **Paolone G**, Encapsulated cell biodelivery of programulin (Research article – under review)  
Grisotto J, Tavakolian Haghghi S, Poor Sasan A, Pedron S, Brunelli M, Moretti U, **Paolone G**. Neurotoxic effects of rotenone and deltamethrin chronic exposure on adult zebrafish (Research article – In prep)  
Grisotto J, Grisotto J, Tavakolian Haghghi S, Poor Sasan A, Pedron S, Brunelli M, Moretti U, **Paolone G**. Neurotoxic Effects of Environmental Diazepam: Insights from Zebrafish Exposure Studies (Research article – In prep)

**INVITED TALK**

Paolone G, Howe WM, Gopalakrishnan M, Decker MW, Sarter M. (2010) Regulation and function of the tonic component of cortical acetylcholine release. In Y. Michotte, Westerink, B., & S. Sarre (Eds.), Monitoring Molecules in Neuroscience. Printer TBD, Brussels.

Sarter M, Parikh V, Howe MW, Gritton H, Paolone G, Lee TM. (2010) Multiple time scales and variable spaces: synaptic neurotransmission *in vivo*. In Y. Michotte, Westerink, B., & S. Sarre (Eds.), Monitoring Molecules in Neuroscience. Printer TBD, Brussels.

Sarter M, Paolone G, Mabrouk OS, Kennedy RT. (2012) Sampling from injured tissue as a blessing in disguise: tonic changes in cholinergic neurotransmission using microdialysis. International Society for Monitoring Molecules in Neuroscience. London, UK.

Falcicchia C, Paolone G, Simonato M. (2017) Cell Therapy for Epilepsy in *Cell Therapy: Current Status and Future Directions*. Springer (Pages 85-97).

*Environmental modulation of psychomotor, subjective, and reinforcing effects of addictive drugs.* - Douglas Hospital Research Center, Neuroscience Division, **McGill University**; Montreal, Dec. 2006

*Conditioning and self-administration of psychostimulants and opiate drugs. Evidences on Neurodegeneration, Plasticity and Repair.* - **Neurofortis, Lund University**; Lund, Sept. 2007

*Conditioning, self administration and extinction of psychostimulants and opiate drugs.* - Department of Psychology, **University of Michigan**; Ann Arbor, MI, Oct. 2007

*Prior daily practice on a sustained attention task synchronizes the increase of prefrontal ACh release and desynchronizes peripheral oscillators.* Department of Psychology, **Michigan State University**, Lansing, MI,

August. 2010.

*Staying cognitively engaged during the wrong time of the day: cognitive cholinergic induction of diurnality and reorganization of multiple circadian rhythms.* - Department of Psychology, **University of Michigan**; Ann Arbor, MI, April 2012

*Prefrontal cholinergic neurotransmission under attentional and pharmacological manipulation in CHT +/+ and CHT +/-.*

CHT summit - Department of Psychology, **University of Michigan**; Ann Arbor, MI, May 2012

*Highly demanding cognitive task and optical stimulation of cholinergic system: old and new approaches to explore mechanisms of attention in rats and mice.* - Institute of Genetics and Biophysics “A. Buzzati-Traverso” **CNR**; **Naples**, Italy, March 2013.

*Taxing the prefrontal cholinergic neurotransmission: an animal model of poor top-down cognitive control of attention and reorganization of multiple circadian rhythms.* Department of Psychology, **University of Trieste**, Italy, June 2014.

*Long-term delivery of GDNF by encapsulated cells for the treatment of epilepsy.* **Marie Skłodowska Curie Action final presentation** in “Epilepsy research in the EU: state of the art and opportunities for the future” – FP7 MC-IAPP – Ferrara, October 28, 2015.

*Reward, Cognition and GDNF: where we are and where we would like to go.* **Italian Institute of Neuroscience**, Section of Verona.– Open neuroscience forum. Verona, Italy, November 17, 2017.

*Reward, Cognition, and Encapsulated cell Therapy with GDNF: “state of the art” and future directions.* Department of Diagnostic and Public Health, **University of Verona**, Italy. May 24th, 2018

*Encapsulated cell therapy for epilepsy: long-term, stable, and efficacious targeting of the hippocampus with GDNF* – **International Association of Advanced Materials Conference**. Stockholm, Sweden. October 9-12, 2018.

*“Encapsulated cell therapy: long-term, stable, and efficacious targeting of subcortical regions with GDNF as a new strategy for neurological disorders”* **Innsbruck Medical School, Department of Pharmacology. Innsbruck, Austria.** March 5<sup>th</sup>, 2019.

*“GDNF: the old and the newest as promising approach for the treatment of epilepsy”* – **Temporal Lobe Epilepsy: a window on the brain** – **NeuroMed** Pozzilli (IS), Italy. May 16-17<sup>th</sup> 2019.

*Encapsulated cell therapy: targeting dopaminergic and cholinergic structural alterations with GDNF as a new strategy in the pathophysiology of neurodegenerative disorders. In “Where dopaminergic and cholinergic systems interact: a gateway for tuning neurological and psychiatric disorders” – Symposium organizer at the Biennial Meeting of the European Behavioural Pharmacology Society, August 28-31 2019 – Braga-Porto, Portugal*

*Delivery GDNF from encapsulated cells: the old and the newest as promising approach for the treatment of neurological and degenerative diseases – International Conference on Alzheimer’s and Dementia. Dubai, September 23-25, 2019*

RESEARCH PRESENTATION

Paolone G, Badiani A (2001) Environmental novelty enhances the locomotor activating but not the analgesic effects of morphine. *Pharmacological Research*, 43 (suppl A):156

Paolone G, Burdino R, Badiani A (2001) Environmental novelty differentially modulates the locomotor activating versus the analgesic effects of acute and repeated morphine. *Society for Neuroscience*. Abstract 26

Paolone G, Palopoli M, Nencini P, Badiani A (2003) Environmental modulation of amphetamine discrimination in the rat. *Behavioural Pharmacology*, 14 (suppl 1): S58

Paolone G, Palopoli M, Nencini P, Badiani A (2003) Environmental novelty facilitates amphetamine discrimination in the rat. *Society for Neuroscience*. Abstract 643.15

Stewart J, Sorge RE, Leri F, Paolone G (2003) The opioid agonist-antagonist, buprenorphine, preferentially suppresses cocaine self-administration over heroin in rats trained to self-administer both drugs. *Society for Neuroscience*. Abstract 109.

Leri F, Tremblay A, Sorge RE, Paolone G, Goddard B, Stewart J (2003) Effects of methadone maintenance on cocaine-motivated behaviour. *Society for Neuroscience*. Abstract 109.16

Sorge RE, Jenkins PA, Paolone G, Stewart J (2003) Effects of amount of exposure to cocaine self-administration and time since termination of drug taking on relapse to drug seeking assessed in extinction and follow acute foot-shock stress. *Society for Neuroscience*. Abstract 421.

Antonilli L, Paolone G, Badiani A, Nencini P (2003) Repeated exposures to heroin and/or cadmium alter the rate of morphine glucuronides in the rat. *Society for Neuroscience*. Abstract 645.6

G. Paolone, D. Caprioli, M. Palopoli, P. Nencini and A. Badiani (2004)

Environmental modulation of the interoceptive effects of cocaine and morphine. EBPS, Rome, Sept 2-4. *Behavioural Pharmacology*, (volume 15, num 5&6).

Paolone G, Caprioli D, Celentano M, Badiani A (2006) Environmental modulation of cocaine self-administration. *Society for Neuroscience*. Abstract 590.2

Caprioli D, Celentano M, Paolone G, Testa A, Badiani A (2006) Environmental modulation of heroin self-administration. *Society for Neuroscience*. Abstract 590.3

Paolone G, Hood S, Stewart J (2007) Effect of inter-trial-interval and duration of exposure on the facilitation of extinction of a cocaine-induced conditioned place preference by d-cycloserine. *Society for Neuroscience*. Abstract 638.2.

Paolone G, Benatar A, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference can be long lasting and resistant to reinstatement: effects of extinction variables. *Canadian Association for Neuroscience*.

Paolone G, Benatar A, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference can be long lasting and resistant to reinstatement: effects of extinction variables. *Canadian College of Neuropsychopharmacology*.

Paolone G, Hood S, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference and Fos Protein Expression in the Pre-Frontal Cortex. *European Behavioral Pharmacology Society*.

Paolone G, Ismail N, Pfaus J, Badiani A, Stewart J. (2008) An established preference for a conditioned stimulus associated with either sucrose or copulation in male rats subsequently shifts to a preference for a conditioned stimulus paired with cocaine self-administration. *Society for Neuroscience*. Abstract 687.

Paolone G, Ji J, Williams S, Howe WM, Ward J, Decker MW, Parikh V, Sarter M. (2009) Effects of the selective alpha 7 nAChR agonist ABT-107 on prefrontal glutamatergic and cholinergic activity and attentional performance. *Society for Neuroscience*. Abstract 227.

Lee TM, Paolone G, Gritton H, Yan J, Hoogerwerf W, Sarter M. (2010) Timed, sustained, attention-demanding performance reorganizes or dampens multiple circadian rhythms. *Society for Research in Biological Rhythms*.

Paolone G, Howe WM, Decker MW, Gopalarishnan, Sarter M. (2010) Multiple modes of cholinergic neurotransmission - Multiple functions. *Society*

for Neuroscience. Abstract 703.

Lee TM, Paolone G, Howe WM, Sarter M. (2010) Staying cognitively engaged during the wrong time of the day: cognitive-cholinergic induction and maintenance of diurnality in rats. *Society for Neuroscience. Abstract 98.*

Gritton H, Howe WM, Hetrick VL, Paolone G, Berke JD, Sarter M. (2010) Optogenetically-evoked cortical cholinergic transients in mice expressing channelrhodopsin-2 (ChR2) in cholinergic neurons. *Society for Neuroscience. Abstract 304.*

Yan J, Paolone G, Bostwick J, Hoogerwerf W, Sarter M, Lee TM. (2010) Daily performance of a sustained attention task during light phase desynchronizes circadian oscillators in nocturnal rats. *Society for Neuroscience. Abstract 499.*

Sarter M, Howe WM, Paolone G. (2011). Real-time biosensing of glutamatergic and cholinergic neurotransmission in vivo: implications for psychopharmacology. *Summer meeting of the British Association for Psychopharmacology. J. of Psychopharmacology. Aug 2011, 25(8): A6-A6.*

Angelakos CC, Paolone G, Meyer PJ, Robinson TE, Sarter M. (2011) Sign-versus goal trackers, top down control of attention, and underlying cholinergic mechanisms. *Society for Neuroscience. Abstract 197.*

Paolone G, Spuz CA, Brisco S, Bradshaw M, Albin RL, Sarter M. (2011) Deficits in attentional control of balance, mobility, and complex movements in a rat model of early state, multisystem Parkinson disease. *Society for Neuroscience. Abstract 244.*

Paolone G, Lamy D, Sarter M, Lee TM. (2011) Cognitive performance-associated increases in cholinergic neurotransmission also serve as a circadian signal to sustain performance-induced diurnal activity pattern. *Society for Neuroscience. Abstract 610.*

Paolone G, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. (2011) Poor and Unstable Sustained Attentional Performance in Sign-Trackers: An Animal Model of Poor Top Down Cognitive Control of Attention. *American College of Neuropsychopharmacology Annual Meeting, December 4-8, HI.*

Sarter M, Howe MW, Paolone G. (2011) Real time biosensing of glutamatergic and cholinergic neurotransmission in vivo: implications for psychopharmacology. In: *Journal of Psychopharmacology. Vol. 25.*

Paolone G, Mabrouk OS, Kennedy RT, Sarter M. (2012) High temporal resolution microdialysis reveals cholinergic spikes preceding upshifts in attentional performance. *Society for Neuroscience 2012 - Abstract selected for nanosymposium.*

Mallory C, Paolone G, Cherian Koshy A, Blakely RD, Sarter M. (2012) Paying attention with a compromised cholinergic system: attenuated activation of cholinergic neurotransmission in attentional task-performing CHT<sup>+/−</sup> mice. *Society for Neuroscience 2012*

Grupe M, Paolone G, Jensen AA, Nielsen KS, Christensen JK, Grunnet M, Sarter M. (2012). Positive allosteric modulation of  $\alpha 4\beta 2^*$  nicotinic acetylcholine receptors augments the amplitudes of prefrontal nicotine-evoked glutamatergic transients. *Society for Neuroscience*.

Kucinsky A, Paolone G, Peterson CC, Ronan EA, Albin RL, Sarter M. (2012). Deficits in the attentional control of posture and complex movements in a rat model of early stage, multisystem Parkinson's disease. *Society for Neuroscience*.

Paolone G, Arcuri A, Brugnoli A, and Morari M (2014). Eltoprazine attenuates L-DOPA induced dyskinesia along with GABA and Glutamate release in rat substantia nigra. *Federation of European Neuroscience Societies*; Milan, Italy.

Paolone G, Tornoe J, Bell W, Fradet T, Emerich DF, Wahlberg LU (2015). Encapsulated cell therapy for Parkinson's disease: long-term, stable and efficacious targeting of the nigrostriatal dopaminergic system with GDNF. *Gordon Research Conference, Catecholamines*. Sunday River, ME, USA.

Falcicchia C, Paolone G, Emerich DF, Bell W, Fradet T, Wahlberg LU, Simonato M (2016). Seizures-suppressant effect of encapsulated BDNF-producing cells in a rat model of temporal lobe epilepsy. *Federation of European Neuroscience Societies*; Copenhagen, Denmark.

Paolone G, Emerich DF, Bell W, Fradet T, Simonato M, Wahlberg LU (2016). Encapsulated cell therapy for epilepsy: long-term, stable and efficacious targeting of the hippocampus with GDNF. *Gordon Research Conference, Mechanisms of Epilepsy & Neural Synchronization*; Girona, Spain.

Pedrazzoli M, Losurdo M, Paolone G, Avesani A, Coco S, Buffelli M (2018). Glucocorticoids deeply affect spine plasticity and inflammation in an animal model of Alzheimer Disease. *Federation of European Neuroscience Societies*; Berlin, Germany.

Lundkvist J, He Y, Rossini MD, Emerich DF, Sandin J, Biverstål H, Blomqvist R, Pollare T, Wahlberg LU, Zhang X, Svenningsson P\* and Paolone G\* (2021). Encapsulated cell-based biodelivery of progranulin improves behaviour in a rat model of parkinson's disease. *AD/PD 2021*.

Grisotto J, Moretti U, and Paolone G (2022). Chronic effects of non-steroidal anti-inflammatory drugs (NSAIDs) and hormones on the animal model Danio

Rerio. International Society of Pharmacovigilance, Verona, Sept 20-22.

Bertasini C, El Hachiri FE, Salzano S, Grisotto J, Silvestri E, Pedron S, Brunelli M, Wahlberg LU, Lundkvist J, and Paolone G (2022). Encapsulated cell therapy for frontotemporal dementia: long-term, stable and efficacious targeting of the striatum with progranulin and GDNF. *Italian Society of Pharmacology, Rome, Nov 16-19.*

Grisotto J, Moretti U, and Paolone G (2022). Pesticides dispersion in aquatic environment: analysis of behavior and histological effects of Rotenone and Deltamethrin exposure on the animal model, Zebrafish. *Italian Society of Pharmacology, Rome, Nov 16-19.*